Home/ Shop/ Weight Management/ RETATRUTIDE 20 MG Peptide

RETATRUTIDE 20 MG Peptide

Retatrutide · 20 MG

≥99% purity by HPLC
Janoshik COA with every lot
Lot-traceable from synthesis
EU-synthesised

In stock · Lot NZM-W-0027 · ships in 3–5 working days (EU)

Available for research procurement. Supplied as a lyophilized research compound with lot-specific COA.

Specifications

Lot NumberNZM-W-0027

Purity99.3% (HPLC)

Verified byJanoshik

Synthesis Date2026-04-15

FormLyophilized powder

StorageBelow 16°C · sealed

Third Party Lab Tested

Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.

Storage & Handling

Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.

FormLyophilized powder

StorageLyophilized: below 16°C for up to 24 months. Reconstituted: refrigerate, use within 30 days.

Reconstitution

Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.

Recommended4 ml BAC water

Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →

Researched Benefits

Weight Reduction up to 24.2% Mean body-weight reduction at 48 weeks in highest published study arm. Liver Fat Reduction up to 86% MASLD substudy: relative MRI-PDFF reduction at 48 weeks. Metabolic Health up to 69.3% improvement HOMA-IR improvement in MASLD substudy. Blood Sugar Control A1C ↓ 1.7–2.0% Phase 2 reduction in highest published study arms.

Product details

The triple agonist frontier.

Retatrutide is an investigational 39-amino-acid peptide characterised as a triple receptor agonist with binding activity at GLP-1R, GIPR and GCGR. This receptor profile distinguishes Retatrutide from single- and dual-pathway incretin analogues: the added glucagon-receptor component introduces a third metabolic signalling axis that published research associates with hepatic energy expenditure and lipid handling. Investigators study the Retatrutide peptide in metabolic and receptor-pharmacology models.

This 20 MG Retatrutide peptide is supplied as a lyophilized research vial within the NZM-Labs peptide line and is intended for laboratory research only. Independent analysis establishes HPLC purity and confirms mass-spectrometry identity for every production lot. Lot-specific documentation accompanies each vial and remains accessible through our Science page, so researchers can match the vial in hand to its own analytical record.

Compound Specs

Research specification table for RETATRUTIDE 20 MG Peptide
Compound	Retatrutide
Sequence length	39 amino acids
Molecular mass	4731.2 Da
Modeled half-life	~6 days (modeled)
Mechanism / research class	GLP-1R / GIPR / GCGR agonist
Example laboratory preparation	4 mL bacteriostatic water (0.9% benzyl alcohol)
Calculated concentration	5 mg per 1.0 mL
Supply format	Retatrutide · 20 MG lyophilized research vial
Storage, lyophilized	Store below 16°C for up to 24 months
Storage, reconstituted	Refrigerate and use within 30 days

Quality standards

Synthesised.
Verified.
Documented.

Wireframe rendering of a research peptide vial alongside molecular structure

Verified Purity

Every lot HPLC-tested by Janoshik Analytical. Independent verification, never in-house only. Current lot: 99.3% (HPLC).

Mass-Spec Confirmed

Identity confirmed by mass spectrometry. Theoretical mass matches measured within 0.5 Da tolerance.

Lyophilized & Sealed

Supplied as lyophilized powder in a sealed crimp-cap vial for laboratory handling and storage.

Lot-Traceable

From synthesis batch to your delivery, every step is logged. Search lot NZM-W-0027 for full traceability.

Evidence base

Backed by research.
Measured in results.

Each tag opens the cited literature behind that effect. References are linked to PubMed.

up to 24.2%

Weight Reduction

Retatrutide is the first reported GLP-1 / GIP / glucagon triple agonist in published research. The added GCGR activation engages hepatic energy expenditure and lipolysis on top of the dual incretin profile, producing a steeper body-weight response than dual agonists in head-to-head reference trials.

Phase 2 trial reported −24.2% mean body-weight reduction at 48 weeks in the highest published study arm.

References

Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. NEJM. 2023;389(6):514-526. PubMed ↗

up to 86%

Liver Fat Reduction

The triple-agonist mechanism is particularly active on hepatic lipid handling. The Retatrutide MASLD substudy reported up to 86% relative liver-fat reduction at 48 weeks - the steepest reduction reported for any incretin analog to date.

References

Sanyal AJ et al. Triple agonist retatrutide on MASLD in a phase 2a substudy. Nat Med. 2024;30:2037-2048. PubMed ↗

up to 69.3% improvement

Metabolic Health

GCGR engagement adds hepatic energy-expenditure modulation to the response envelope. Research populations show improvements on HOMA-IR and broader insulin-sensitivity markers consistent with the triple-pathway profile.

References

Sanyal AJ et al. Nat Med. 2024;30:2037-2048. PubMed ↗

A1C ↓ 1.7–2.0%

Blood Sugar Control

Despite GCGR activation (which can theoretically raise hepatic glucose output), net glycemic effect in research populations remains strongly negative - A1C reductions of 1.7–2.0% reported in the phase 2 trial across the higher dose arms.

References

Rosenstock J et al. Retatrutide in T2D. The Lancet. 2023;402(10401):529-544. PubMed ↗

Specific to RETATRUTIDE 20 MG Peptide

Frequently Asked Questions

(01)

What does the third receptor add over Tirzepatide?

Glucagon-receptor activation engages hepatic glucose output and lipolysis. The net effect in research models is a broader metabolic response, particularly on lipid-handling endpoints, where dual agonists trail.

(02)

How is the Certificate of Analysis verified?

Every lot is sent to Janoshik Analytical for independent HPLC and mass spectrometry testing. The COA you receive is theirs, not ours - searchable by lot number on our Science page, no account required.

(03)

How is the product shipped?

Lyophilized vials are shipped across the EU. Store sealed vials below 16°C after delivery. Typical delivery takes 3–5 working days.

(04)

Is this a research product?

Yes. NZM peptides are sold strictly for in vitro and animal research use only. They are not for human consumption, off-label use, or clinical application. Please consult applicable local regulations before ordering.

(05)

What is the Retatrutide research peptide price?

The current Retatrutide price is shown on this page. Pricing applies to B2B research procurement only and may vary by lot, format, and availability.

(06)

Can research customers buy Retatrutide from NZM-Labs?

Yes. Research customers can order Retatrutide through NZM-Labs for in vitro and animal research use only. It is not sold for human consumption, clinical use, or self-administration.

Researcher reviews